The agreement stipulates that upon the effective time of the merger, Carvix's existing shareholders will receive a total of 50,000,001 shares of Crown Reserve's common stock, allocated according to a specified schedule. Additionally, there is a contingent earnout provision allowing eligible Carvix equityholders to earn up to 50,000,100 additional shares based on achieving certain financial milestones over the next four years. These milestones include specific EBITDA and revenue targets, which are set to incentivize performance and align the interests of the management teams of both companies.
The transaction is subject to customary closing conditions, including stockholder approvals and regulatory clearances. The boards of both companies have unanimously approved the agreement, indicating strong confidence in the strategic fit and potential synergies of the merger. The combined entity aims to leverage Carvix's innovative automotive solutions and Crown Reserve's financial resources to drive growth and enhance shareholder value.
Crown Reserve's management has expressed optimism about the merger, highlighting the strategic advantages it brings, including expanded market access and enhanced operational efficiencies. The transaction is expected to close in the second half of 2026, pending the necessary approvals and completion of due diligence. This merger represents a pivotal moment for Crown Reserve as it seeks to solidify its position in the competitive automotive market and deliver long-term value to its shareholders.
